Vivreon Biosciences Wins JLABS San Diego QuickFire Challenge

SAN DIEGO - March 14, 2018 - PRLog -- Vivreon Biosciences, LLC, announces their selection as the winner of the JLABS San Diego QuickFire Challenge. The award includes $25,000 in grant funding, one year of lab space at Johnson & Johnson Innovation, JLABS (JLABS San Diego), access to the JLABS community, and mentorship from Johnson & Johnson Innovation.

The QuickFire Challenge was offered to attract cutting edge, early-stage innovation that will provide potential solutions to patients from across the world.

"The field of applicants was filled with pioneering companies and we are enormously grateful and excited to receive this award," said Vivreon Chief Operations Officer Andrew Newman, Ph.D. "JLABS has a magnificent reputation and we are thrilled to continue our hard work as the newest member of that community."

Vivreon is developing therapies to treat Alzheimer's disease with a unique approach using small molecule inhibitors of the calcium release activated calcium (CRAC) channel, a central regulator of neuroinflammation. Recent evidence suggests that chronic inflammation in the brain plays a major role in Alzheimer's disease initiation and pathogenesis, with CRAC channel activation in microglial cells occurring during the initial phase of inflammation. By targeting this upstream pathway, Vivreon hopes to dampen inflammation before neuronal damage occurs.

The award was announced at the 8^th Annual Biocom Global Life Science Partnering Conference. Vivreon President Milton Greenberg, Ph.D., accepted the award saying, "We see this as another validation of our drug target and a testament to the incredible work that our team here at Vivreon has done to reach this point."

Vivreon Biosciences, LLC was founded in 2014 in San Diego, California. In addition to Alzheimer's disease, Vivreon's pipeline includes CRAC-targeted small molecule therapeutics for Parkinson's disease and ulcerative colitis. For more information, please visit http://www.vivreonbiosciences.com.